deltatrials
Completed PHASE2 INTERVENTIONAL 3-arm NCT00800332

Dose Finding Study With CYT003-QbG10 in Patients With House Dust Mite Allergy

Double-blind, Placebo-controlled Dose-finding Study With CYT003-QbG10 in Adult Patients With Rhinoconjunctivitis Due to House Dust Mite Allergy

Sponsor: Cytos Biotechnology AG

Conditions Allergies Rhinoconjunctivitis
Interventions CYT003-QbG10 Placebo
Updated 5 times since 2017 Last updated: Nov 11, 2010 Started: Nov 30, 2008 Primary completion: Apr 30, 2010 Completion: Nov 30, 2010
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Allergies and Rhinoconjunctivitis, this trial is completed. The trial is conducted by Cytos Biotechnology AG and has accumulated 5 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 23 months · monthly snapshotCompleted

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Nov 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Cytos Biotechnology AG
Data source: Cytos Biotechnology AG

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations